SCHEDULE 13G
 
Amendment No. 0
ARROWHEAD RESEARCH CORP
Common Stock
Cusip #042797209
 
Cusip #042797209
Item 1: 	   	Reporting Person - FMR LLC
Item 4: 	   	Delaware
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	5,029,178
Item 8: 	   	0
Item 9: 	   	5,029,178
Item 11: 	  	11.292%
Item 12: 	  	HC
 
Cusip #042797209
Item 1: 	   	Reporting Person - Edward C. Johnson 3d
Item 4: 	   	United States of America
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	5,029,178
Item 8: 	   	0
Item 9: 	   	5,029,178
Item 11: 	  	11.292%
Item 12: 	  	IN
 
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
 
Item 1(a). 	    	Name of Issuer:
 
  	  	          	ARROWHEAD RESEARCH CORP
 
Item 1(b). 	    	Name of Issuer's Principal Executive Offices:
 
  	  	          	201 South Lake Avenue
Suite 703
  	  	          	Pasadena, CA 91101
  	  	          	
 
Item 2(a). 	     	 Name of Person Filing:
 
  	   	               	 FMR LLC
 
Item 2(b). 	     	 Address or Principal Business Office or, if None, 
Residence:
 
  	   	               	 245 Summer Street, Boston, Massachusetts 02210
 
Item 2(c). 	     	 Citizenship:
 
  	   	               	 Not applicable
 
Item 2(d). 	     	 Title of Class of Securities:
 
  	   	               	 Common Stock
 
Item 2(e). 	     	 CUSIP Number:
 
  	   	               	 042797209
 
Item 3. 	    	This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) 
and the person filing,
FMR LLC, is a parent holding company in accordance with Section 240.13d-
1(b)(ii)(G).   (Note:  See Item 7).
 
Item 4. 	    	Ownership
 
  	  	     	(a)    Amount Beneficially Owned: 	5,029,178
 
  	  	     	(b)    Percent of Class: 	11.292%
 
  	  	     	(c)    Number of shares as to which such person has:
 
  	  	     	       (i)    sole power to vote or to direct the vote: 	0
 
  	  	     	       (ii)    shared power to vote or to direct the vote: 	0
 
  	  	     	       (iii)    sole power to dispose or to direct the 
disposition of: 	5,029,178
 
  	  	     	       (iv)    shared power to dispose or to direct the 
disposition of: 	0
 
Item 5. 	    	Ownership of Five Percent or Less of a Class.
 
  	    	     	Not applicable.
 
Item 6. 	    	Ownership of More than Five Percent on Behalf of Another 
Person.
 
  	    	     	Various persons have the right to receive or the power to 
direct the receipt of dividends from, or the proceeds from the sale of, the 
Common Stock of ARROWHEAD RESEARCH CORP. The interest of one person, Select 
Biotechnology Portfolio, an investment company registered under the 
Investment Company Act of 1940, in the Common Stock of ARROWHEAD RESEARCH 
CORP, amounted to 3,109,885 shares or 6.983% of the total outstanding 
Common Stock at February 28, 2014.
 
Item 7. 	    	Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent Holding Company.
 
  	    	     	See attached Exhibit A.
 
Item 8. 	    	Identification and Classification of Members of the Group.
 
  	    	     	Not applicable. See attached Exhibit A.
 
Item 9. 	    	Notice of Dissolution of Group.
 
  	    	  	Not applicable.
 
Item 10. 	    	Certification.
 
  	    	     	

By signing below I certify that, to the best of my knowledge and belief, 
the securities referred to above were acquired in the ordinary course of 
business and were not acquired for the purpose of and do not have the 
effect of changing or influencing the control of the issuer of such 
securities and were not acquired in connection with or as a participant in 
any transaction having such purpose or effect.

 
Signature
 
  	    	     	

After reasonable inquiry and to the best of my knowledge and belief, I 
certify that the information set forth in this statement is true, complete 
and correct.

  	March 7, 2014
  	Date
 
  	/s/ Scott C. Goebel
  	Signature
 
  	Scott C. Goebel
  	 Duly authorized under Power of Attorney effective as of June 1, 2008, 
by and on behalf of FMR LLC and its direct and indirect subsidiaries
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
 

                Pursuant to the instructions in Item 7 of Schedule 13G, 
Fidelity Management & Research Company ("Fidelity"), 245 Summer Street, 
Boston, Massachusetts 02210, a wholly-owned subsidiary of FMR LLC and an 
investment adviser registered under Section 203 of the Investment Advisers 
Act of 1940, is the beneficial owner of 445,435 shares or 1.000% of the 
Common Stock outstanding of ARROWHEAD RESEARCH CORP ("the Company") as a 
result of acting as investment adviser to various investment companies 
registered under Section 8 of the Investment Company Act of 1940. The 
number of shares of Common Stock of ARROWHEAD RESEARCH CORP owned by the 
investment companies at February 28, 2014 included 35,035 shares of Common 
Stock resulting from the assumed conversion of 350,347 shares of ARROWHEAD 
RSCH WT 5/21/17 PIPE (0.1 shares of Common Stock for each Warrant).

 

                The ownership of one investment company, Select 
Biotechnology Portfolio, amounted to 3,109,885 shares or 6.983% of the 
Common Stock outstanding. Select Biotechnology Portfolio has its principal 
business office at 245 Summer Street, Boston, Massachusetts 02210.

 

                Edward C. Johnson 3d and FMR LLC, through its control of 
Fidelity, and the funds each has sole power to dispose of the 445,435 
shares owned by the Funds.

 

                 Fidelity SelectCo, LLC ("SelectCo"), 1225 17th Street, 
Suite 1100, Denver, Colorado 80202, a wholly-owned subsidiary of FMR LLC 
and an investment adviser registered under Section 203 of the Investment 
Advisers Act of 1940, is the beneficial owner of 4,583,743 shares or 
10.292% of the Common Stock outstanding of ARROWHEAD RESEARCH CORP ("the 
Company") as a result of acting as investment adviser to various investment 
companies registered under Section 8 of the Investment Company Act of 1940 
(the "SelectCo Funds").

 

                Edward C. Johnson 3d and FMR LLC, through its control of 
SelectCo, and the SelectCo Funds each has sole power to dispose of the 
4,583,743 owned by the SelectCo Funds.

 

                Members of the family of Edward C. Johnson 3d, Chairman of 
FMR LLC, are the predominant owners, directly or through trusts, of Series 
B voting common shares of FMR LLC, representing 49% of the voting power of 
FMR LLC. The Johnson family group and all other Series B shareholders have 
entered into a shareholders' voting agreement under which all Series B 
voting common shares will be voted in accordance with the majority vote of 
Series B voting common shares. Accordingly, through their ownership of 
voting common shares and the execution of the shareholders' voting 
agreement, members of the Johnson family may be deemed, under the 
Investment Company Act of 1940, to form a controlling group with respect to 
FMR LLC.

 

                Neither FMR LLC nor Edward C. Johnson 3d, Chairman of FMR 
LLC, has the sole power to vote or direct the voting of the shares owned 
directly by the Fidelity Funds, which power resides with the Funds' Boards 
of Trustees. Fidelity carries out the voting of the shares under written 
guidelines established by the Funds' Boards of Trustees.

 
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
RULE 13d-1(f)(1) AGREEMENT
 

                The undersigned persons, on March 7, 2014, agree and 
consent to the joint filing on their behalf of this Schedule 13G in 
connection with their beneficial ownership of the Common Stock of ARROWHEAD 
RESEARCH CORP at February 28, 2014.

 
  	FMR LLC
 
  	By /s/ Scott C. Goebel
  	Scott C. Goebel
  	Duly authorized under Power of Attorney effective as of June 1, 2008, by 
and on behalf of FMR LLC and its direct and indirect subsidiaries
 
  	Edward C. Johnson 3d
 
  	By /s/ Scott C. Goebel
  	Scott C. Goebel
  	Duly authorized under Power of Attorney effective as of June 1, 2008, by 
and on behalf of Edward C. Johnson 3d
 
  	Fidelity Management & Research Company
 
  	By /s/ Scott C. Goebel
  	Scott C. Goebel
  	Senior V.P. and General Counsel
 
  	Select Biotechnology Portfolio
 
  	By /s/ Scott C. Goebel
  	Scott C. Goebel
  	Secretary

Document-Separator. This page separates the filing documents of two 
notifications.

Page   of  

Exhibit A